Brote psicótico agudo y rabdomiólisis tras el uso de lovastatina

Article information

Resumen

Introducción

Las estatinas son los medicamentos más recetados en el mundo, por el beneficio y la seguridad que ofrecen. Sin embargo, pueden causar reacciones adversas a escala neurológica, gastrointestinal, renal y muscular.

Objetivo

Es describir el curso clínico de una paciente con reacción adversa medicamentosa a la lovastatina.

Métodos

Reporte de caso y revisión de la literatura.

Resultados

Mujer de 52 años con psicosis súbita y rabdomiólisis secundaria al consumo de lovastatina, clínica que remite con la suspensión del fármaco. La relación causal se establece a través de la escala de Naranjo, con puntuación de 6 (probable reacción adversa medicamentosa).

Conclusión

La manifestación simultánea de psicosis y rabdomiólisis representa un caso clínico atípico y único consecuente a la ingesta de lovastatina.

Palabras clave:

Psicosis

rabdomiólisis

lovastatina

reacción adversa medicamentosa

Abstract

Introduction

Statins are the most prescribed drugs worldwide given the benefit and security they offer. However, they can cause severe neurological, gastrointestinal, renal and muscular side effects.

Objective

To describe the clinical course of a female patient with adverse drug reaction to Lovastatin.

Methods

Case report and literature review.

Results

52-year old woman with sudden psychosis and rhabdomyolysis secondary to Lovastatin and ending after the drug suspension. The causal relationship was corroborated with a score of 6 (probable ADR) on Naranjo's Scale.

Conclusions

The simultaneous manifestation of psychosis and rhabdomiolysis represents an atypical and unique case following Lovastatin ingestion.

Key words:

Psychosis

rhabdomyolysis

lovastatin

adverse drug reaction

Full text is only aviable in PDF

Referencias

[1]

JR Downs, M Clearfield, S Weis, et al.

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/Tex CAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

J Am Med Assoc, 279 (1998), pp. 1615-1622

[2]

SE Nissen, SJ Nicholls, L Sipahi.

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.

J Am Med Assoc, 295 (2006), pp. 1556-1565

[3]

M Antonio, J Gotto.

Statins, cardiovascular disease, and drug safety.

Am J Cardiol, 97 (2006), pp. S3-S5

[4]

MH Davidson.

Safety profiles for the HMG-CoA reductase inhibitors: treatment and trust.

Drugs, 61 (2001), pp. 197-206

Medline

[5]

C Vaklavas, YS Chatzizisis, A Ziakas, et al.

Molecular basis of statin-associated myopathy.

Atherosclerosis, 202 (2009), pp. 18-28

http://dx.doi.org/10.1016/j.atherosclerosis.2008.05.021 | Medline

[6]

RS Rosenson.

Current overview of statin-induced myopathy.

Am J Med, 116 (2004), pp. 408-416

Medline

[7]

E Melgarejo.

Dislipidemias: Guías de Manejo, Thomsom PLM, (2009),

[8]

J Simons.

The $10 billion pill.

Fortune, 147 (2003), pp. 58-62

Medline

[9]

X Bosch, E Poch, JM Grau.

Rhabdomyolysis and acute kidney injury.

N Eng J Med, 361 (2009), pp. 62-72

[10]

KA Antons, CD Williams, SK Baker, et al.

Clinical perspectives of statin-induced rhabdomyolysis.

Am J Med, 119 (2006), pp. 400-409

http://dx.doi.org/10.1016/j.amjmed.2006.02.007 | Medline

[11]

RL Wortmann, RW Tipping, JG Levine, et al.

Frequency of myopathy in patients receiving lovastatin.

Am J Cardiol, 95 (2005), pp. 983-985

http://dx.doi.org/10.1016/j.amjcard.2004.12.042 | Medline

[12]

C Venero, P Thompson.

Managing statin myopathy.

Endocrinol Metab Clin North Am, 38 (2009), pp. 121-136

http://dx.doi.org/10.1016/j.ecl.2008.11.002 | Medline

[13]

A Saheki, T Terasaki, I Tamai, et al.

In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors.

Pharm Res, 11 (1994), pp. 305-311

Medline

[14]

L Galatti, G Polimeni, F Salvo, et al.

Short-term memory loss associated with rosuvastatin.

Pharmacotherapy, 26 (2006), pp. 1190-1192

http://dx.doi.org/10.1592/phco.26.8.1190 | Medline

[15]

CA Naranjo, U Busto, EM Sellers, et al.

A method for estimating the probability of adverse drug reactions.

Clin Pharmacol Ther, 30 (1981), pp. 239-245

Medline

[16]

BC Lund, RM Carnahan, JA Egge, et al.

Inappropriate prescribing predicts adverse drug events in older adults.

Ann Pharmacother, 44 (2010), pp. 957-963

http://dx.doi.org/10.1345/aph.1M657 | Medline

[17]

BA Golomb.

Implications of statin adverse effects in the elderly.

Expert Opin Drug Saf, 4 (2005), pp. 389-397

http://dx.doi.org/10.1517/14740338.4.3.389 | Medline

[18]

H Sinzinger, F Mayr, P Schmid, et al.

Sleep disturbance and appetite loss after lovastatin [letter].

Lancet, 343 (1994), pp. 973

Medline

[19]

A Orsi, O Sherman, Z Woldeselassie.

Simvastatin-associated memory loss.

Pharmacother, 21 (2001), pp. 767-769

[20]

GP Parale, NN Baheti, PM Kulkarni, et al.

Effects of atorvastatin on higher functions.

Eur J Clin Pharmacol, 62 (2006), pp. 259-265

http://dx.doi.org/10.1007/s00228-005-0073-z | Medline

[21]

M Tuccori, F Lapi, A Testi, et al.

Statin-associated psychiatric adverse events: a case/non-case evaluation of an italian database of spontaneous adverse drug reaction reporting.

Drug Safety, 31 (2008), pp. 1115-1123

Medline

[22]

JF Whitfield.

Can statins put the brakes on Alzheimer's disease?.

Expert Opin Investig Drugs, 15 (2006), pp. 1479-1485

http://dx.doi.org/10.1517/13543784.15.12.1479 | Medline

[23]

DL Sparks, DJ Connor, MN Sabbagh, et al.

Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer'sdisease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial.

Acta Neurol Scand, 114 (2006), pp. 3-7

[24]

HD Scott, K Laake.

Statins for the reduction of risk of Alzheimer's disease.

Cochrane Database Sys Rev, (2001),

[25]

BA Golomb, T Kane, JE Dimsdale.

Severe irritability associated with statin cholesterol-lowering drugs.

QJM, 97 (2004), pp. 229-235

Medline

[26]

JT Peters, CL Garwood, M Lepczyk.